Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

523
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
523
Vaccinations01:51

Vaccinations

46.7K
Overview
46.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rotavirus Vaccine Coverage and Potential Barriers Among US Children Born From 2007 to 2024.

Pediatrics·2026
Same author

Impact of Rotavirus Vaccine on Rotavirus Diarrhea-Associated Hospitalizations among Children under 5 Years of Age in Uganda.

Journal of the Pediatric Infectious Diseases Society·2026
Same author

Real-World Effectiveness of Rotavirus Vaccine Against Rotavirus Disease Among Children < 2 Year of Age in Mali.

Journal of the Pediatric Infectious Diseases Society·2026
Same author

Effectiveness of monovalent rotavirus vaccine among young children in Pakistan: a test-negative case-control evaluation.

Vaccine·2026
Same author

Clinical, Molecular and Evolutionary Characterization of Noroviruses in Hospitalized Children With Acute Gastroenteritis in Vietnam, 2016 to 2021.

Journal of medical virology·2026
Same author

Rotavirus-specific IgA and IgG Patterns During the First Two Years of Life in the PREVAIL Birth Cohort.

The Journal of infectious diseases·2026
Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026
Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026
Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026
Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026
Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026
Same journal

Optimizing biologic therapy in psoriasis: dose adjustment, treatment duration, and tapering-an expert perspective.

Expert opinion on biological therapy·2026
See all related articles

Related Experiment Video

Updated: Oct 21, 2025

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
10:49

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus

Published on: January 28, 2019

9.0K

Rotavirus vaccines: progress and new developments.

Jordan E Cates1,2, Jacqueline E Tate1, Umesh Parashar1

  • 1Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, USA.

Expert Opinion on Biological Therapy
|September 6, 2021
PubMed
Summary
This summary is machine-generated.

Rotavirus vaccines significantly reduce severe gastroenteritis and deaths in young children globally. Ongoing research aims to improve vaccine effectiveness, especially in low-resource settings.

Keywords:
Rotavirusgastroenteritissafetyvaccination coveragevaccine

More Related Videos

Simplified Reverse Genetics Method to Recover Recombinant Rotaviruses Expressing Reporter Proteins
11:40

Simplified Reverse Genetics Method to Recover Recombinant Rotaviruses Expressing Reporter Proteins

Published on: April 17, 2020

9.0K
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.2K

Related Experiment Videos

Last Updated: Oct 21, 2025

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
10:49

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus

Published on: January 28, 2019

9.0K
Simplified Reverse Genetics Method to Recover Recombinant Rotaviruses Expressing Reporter Proteins
11:40

Simplified Reverse Genetics Method to Recover Recombinant Rotaviruses Expressing Reporter Proteins

Published on: April 17, 2020

9.0K
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.2K

Area of Science:

  • Vaccinology
  • Pediatric Infectious Diseases
  • Public Health

Background:

  • Rotavirus is a leading cause of severe gastroenteritis in children under five, responsible for substantial annual mortality.
  • Six oral, live-attenuated rotavirus vaccines are available, with four WHO-pre-qualified for global use.
  • Widespread vaccination has decreased rotavirus hospitalizations and diarrhea deaths in countries with vaccine introduction.

Purpose of the Study:

  • To review current rotavirus vaccines, their global coverage, and efficacy/effectiveness.
  • To summarize vaccine safety data, including intussusception risk.
  • To provide an overview of rotavirus vaccines in development.

Main Methods:

  • Comprehensive literature review of clinical trials and post-licensure evaluations.
  • Analysis of global vaccine coverage data.
  • Synthesis of safety data, focusing on intussusception risk.

Main Results:

  • Rotavirus vaccines demonstrate high effectiveness (80-90%) in high-income countries.
  • Effectiveness is lower (40-70%) in low-to-middle-income countries.
  • Ongoing surveillance and research are crucial for understanding and improving vaccine performance.

Conclusions:

  • Rotavirus vaccines are highly effective but show variable performance across different economic settings.
  • Further research is needed to identify factors influencing effectiveness and to develop next-generation vaccines.
  • Continued surveillance and data strengthening are essential for optimizing rotavirus vaccine impact.